BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32336420)

  • 21. Tagraxofusp in myeloid malignancies.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
    Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Lane AA
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):589-600. PubMed ID: 32336422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
    Pemmaraju N; Konopleva M
    Blood Adv; 2020 Aug; 4(16):4020-4027. PubMed ID: 32841341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
    Beziat G; Ysebaert L
    Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective.
    Deconinck E
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):613-620. PubMed ID: 32336424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
    Gulati R; Abu-Salah A; Salous T; Nassiri M
    J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Morin A; Kechedjian F; Walton P; Tavakoli A
    Clin J Oncol Nurs; 2021 Apr; 25(2):E10-E16. PubMed ID: 33739343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Xue T; Budde LE
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
    Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
    Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High ORRs Seen with Tagraxofusp-erzs in BPDCN.
    Cancer Discov; 2019 Jul; 9(7):OF1. PubMed ID: 31126990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
    Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
    Pemmaraju N; Kantarjian H
    Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
    Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
    Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.